M&A Alert . Two Deals Drop March 24, 2026

Thermo Fisher (TMO) acquiring Clario Holdings for $8.875 billion cash. Clario is a leading clinical research technology company that provides endpoint data solutions, imaging, cardiac safety, and decentralized trial capabilities to pharma and biotech. They're the picks-and-shovels play for clinical trials. Thermo Fisher adding Clario bolsters their life sciences services and clinical research infrastructure. This is Thermo doing what Thermo does, buying the infrastructure layer that every drug company depends on.

Gilead (GILD) acquiring Ouro Medicines for $2 billion cash. Gilead continuing to bolt on pipeline assets to fill gaps in their portfolio. Classic big pharma playbook, let the small companies take the clinical risk, then buy the winners.

Nearly $11 billion in M&A announced on a single Monday. M&A is not dead, it's just been waiting for valuations to come down. When you see big pharma and life sciences companies writing checks this size mid-March, that's the signal. The buyers are active and the bid-ask spread is narrowing. The question for our universe is always the same, who's next.